Arcera Life Sciences and Innogen Sign Exclusive Licensing Agreement for GLP-1 Therapy
Abu Dhabi-headquartered Arcera Life Sciences and China-based Innogen Pharmaceuticals have entered into an exclusive licensing and commercialization agreement for Efsubaglutide Alfa, a GLP-1 receptor agonist therapy. The partnership covers key international markets including the UAE, Africa, Eastern Europe, and Latin America, with a total potential deal value exceeding US$1 billion.

